Diabetes, Heart and Cardiovascular Diseases News Chronicle.  Diabetes, Cardiovascular and Heart Diseases
 Article 74
    Published on October 26, 2016


Music Streaming Pillow From Zeeq

Previously done studies on sleep indicated that music can help people to sleep better. But playing music may disturb others. One can use headphones but they are uncomfortable while sleeping. A pillow from Zeeq can play music with low volume supported by eight wireless speakers, just for you without disturbing others. The product uses iTunes and app in playing music. One can track and optimize their sleep patterns. The product gently vibrates if you snore so that you can wake up and adjust your sleeping position.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. About Beat2Phone Wearable Device To Check Heart Health
2. Thim Wearable Device For Better Sleep
3. Personalized Diet And Fitness Device & App From STYR Labs
4. Device To Find Out Internal Inflammation

 

 

About DPP-4 Diabetes Drugs Januvia and Janumet To Lower Blood Sugar Levels

Januvia and Janumet (combination drug of Januvia) are type 2 diabetes (T2D) drugs intended to lower blood sugar levels from Merck franchise. These two drugs are classified as DPP-4 (enzyme dipeptidyl peptidase-4) inhibitors. In a normal individual without type 2 diabetes (T2D), enzyme dipeptidyl peptidase-4 (produced in the body) removes incretin from the human body. If a diabetes patient is lacking enzyme dipeptidyl peptidase-4, he requires DPP-4 inhibitors to prevent low blood sugar levels and weight gain. Other drugs of this class are

  • Squibb from Bristol-Myers
  • Onglyza from AstraZeneca
  • Galvus (not in the United States) from Novartis
  • Tradjenta from Eli Lilly
  • Nesina from Takeda

Recently FDA confirmed that the Merck drugs have

  • High safety profile
  • No risk to major adverse cardiovascular events
  • No risk to hospitalization for heart failure


       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. DPP-4 Inhibitor Linagliptin Tradjenta Prevents Cardiovascular Disease (CVD)
2. More Accurate Procedure To Find Sugar Levels
3. About Medtronic Sugar.IQ
4. About Whoop Wearable Device

 

Incretin : Blood glucose levels will be lowered by an increase in insulin production from pancreas due to the stimulation of the group of metabolic hormones called Incretin. There are two important incretin hormones secreted by endocrine cells

  • Glucose-dependent insulinotropic peptide, also known as gastric inhibitory peptide (GIP)
  • Glucagon-like peptide-1 (GLP-1)

 

Neovacs Vaccine To Treat Type 1 Diabetes (T1D)

There is a number of companies around the world working on multiple technologies to make the life of a diabetes patient easier but only a few companies to cure the diabetes autoimmune disease. France based Neovacs biotech company is in the field of developing therapies for autoimmune diseases. The company says they are planning to develop a vaccine for T1D along with researchers from Cochin Hospital in Paris. They are going to conduct preclinical studies in mice models to check the ability of IFN-Kinoid to treat type 1 diabetes (T1D) disease. We have to wait until clinical results were published.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Study On Occurrence Of type 1 Diabetes
2. About type 1 disease (T1D) And type 2 Diabetes (T2D)
3. Study On Wearable Technology Devices
4. Device To Detect Deadly Ketones

 

 

About Omada's Program Intended To Reduce Overweight Or Obesity

Overweight and obesity of senior citizens were reduced by the digital behavioral health coaching program from Omada Health, San Francisco. Previous research studies linked to weight gain to increased risk for the development of chronic diseases such as diabetes and heart diseases. Researchers studied 1,121 adult individuals for a period of 3 years duration with age 65 years or above, with baseline body mass index (BMI) of 24 or more with diabetes and heart disease risks. Features of the digital behavioral health coaching program are

  • Online educational program for 16 weeks
  • To bring behavioral changes
  • A social network support group
  • A professional health coach for guidance
  • Digital tracking tools such as activity tracker and wireless scale

After six months during the program

  • At least 9 of the 16 lessons in the program were completed by 90 percent of the participants
  • Individuals lost 6.8 percent of body weight on average
  • Each individual saved USD 1,770
  • Additional savings during the next decade

The above study shows Omada health program gives significant health savings and health outcomes for senior citizens aged 65 or above. HHS announced that Medicare is going to cover Diabetes Prevention Program including digital versions such as Omadas. Sean Duffy is the CEO and co-founder of Omada Health. Cynthia Castro Sweet is one of the study authors and also Director of Medical Affairs.



       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and paste the code below) :

Articles similar to this topic


1. Link Between Obesity Or Overweight Or BMI And Marriage Status
2. Risk To Liver Cancer Increases With Increase In Obesity Or BMI
3. Cancer Risk With Obesity
4. Wristbands, Headbands, Skin Patches And Wearable Devices From Eccrine Systems

 

 

 

Site maps

Site map 1   Site map 2   Site map 3   Site map 4


The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.